[ A23-106] Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66
Last updated 21.12.2023
Project no.:
A23-106
Commission:
Commission awarded on 08.11.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy
- If high-dose therapy is an option: Unchanged after addendum: added benefit not proven
- If high-dose therapy is not an option: Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A23-106
| Project no. | Title | Status |
|---|---|---|
| A23-66 | Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-12-21 A G-BA decision was published.